Analysts at Peel Hunt began coverage on shares of Silence Therapeutics (LON:SLN) in a note issued to investors on Thursday. The brokerage set a “buy” rating and a GBX 276 ($3.71) price target on the stock. Peel Hunt’s target price would suggest a potential upside of 40.10% from the company’s current price.

Shares of Silence Therapeutics (LON SLN) opened at GBX 197 ($2.65) on Thursday. Silence Therapeutics has a 12-month low of GBX 71.88 ($0.97) and a 12-month high of GBX 254.75 ($3.43).

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at

Silence Therapeutics Company Profile

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with's FREE daily email newsletter.